Accept Cookies?
Provided by OpenGlobal E-commerce

Please wait while your page loads ...

FARAFARA Cure FA

Penwest Pharmaceuticals (PPCO) Announces Results of Phase Ib Trial of A0001

Penwest Pharmaceuticals Co. (Nasdaq: PPCO) announced the results of its Phase Ib clinical trial of A0001, a compound the Company is developing for the treatment of mitochondrial diseases. Drs. Amale Hawi, Senior Vice President, Pharmaceutical Development, and Thomas Sciascia, Senior Vice President & Chief Medical Officer, will be presenting these results at the Friedreich's Ataxia Therapeutics Meeting on Friday, July 17, 2009, in Philadelphia, PA.

In the Phase Ib trial, the drug was well tolerated by subjects, and no serious adverse events were reported. There was a dose-dependent increase in exposure approaching steady state within 2-4 days following repeat-dosing, and a maximum tolerated dose was established.

Read More: Penwest Pharmaceuticals (PPCO) Announces Results of Phase Ib Trial of A0001

SHARE

FacebookTwitterLinkedInYoutube
Event A.jpg

News & Press Archives